Myriad Genetics CSO Jerry Lanchbury to retire effective Jan 14, 2022

MYRIAD GENETICS INC

Dr. Jerry Lanchbury notified retirement as Chief Scientific Officer.
Retirement effective January 14, 2022.
Company expects to enter a separation and consulting agreement (terms to be filed later).
No replacement has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jerry Lanchbury

Chief Scientific Officer

MYGN · MYRIAD GENETICS INC

Effective: 2022-01-14
Filed: January 4, 2022, 6:59 PM ET

On January 3, 2022, Jerry Lanchbury, Ph.D., notified Myriad Genetics, Inc. (the "Company") of his retirement as Chief Scientific Officer of the Company, effective January 14, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jerry Lanchbury retired as Chief Scientific Officer at MYRIAD GENETICS INC.

Action: retired
Role: Chief Scientific Officer

Exact text from the filing

On January 3, 2022, Jerry Lanchbury, Ph.D., notified Myriad Genetics, Inc. (the "Company") of his retirement as Chief Scientific Officer of the Company, effective January 14, 2022.

View on SEC.gov

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-22-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.